NEW YORK, Sept. 8, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of C3.ai, Inc. (“C3.ai” or “the Company”) (NYSE: AI). Investors who purchased C3.ai securities are encouraged to obtain additional…
Month: September 2024
NEW YORK, Sept. 8, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Xiao-I Corporation (“Xiao-I” or “the Company”) (NASDAQ: AIXI). Investors who purchased Xiao-I securities are encouraged to obtain…
NEW YORK, Sept. 8, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV) and…
NEW YORK, Sept. 8, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GitLab Inc. (“GitLab” or “the Company”) (NASDAQ: GTLB) and certain of its officers….
NEW YORK, Sept. 8, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ZoomInfo Technologies, Inc. (“ZoomInfo” or “the Company”) (NASDAQ: ZI) and certain of…
SAR satellites and data enable Greece to monitor their areas of interest and improve their natural catastrophe detection and maritime awareness capabilities. HELSINKI, Sept. 8, 2024 /PRNewswire/ — ICEYE, the global leader in synthetic aperture radar (SAR) satellite operations for Earth…
SAR satellites and data enable Greece to monitor their areas of interest and improve their natural catastrophe detection and maritime awareness capabilities. HELSINKI, Sept. 8, 2024 /PRNewswire/ — ICEYE, the global leader in synthetic aperture radar (SAR) satellite operations for Earth…
HONG KONG, Sept. 8, 2024 /PRNewswire/ — Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combination with chemotherapy, for the perioperative…
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy Results from an interim analysis featured in late-breaker oral presentation at WCLC SAN DIEGO, Sept. 8,…
NEW YORK, Sept. 8, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between October 12, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important September 10,…